Skip to main content
PMC home page
Animal Cells and Systems logoLink to Animal Cells and Systems
. 2019 Jun 9;23(3):170–175. doi: 10.1080/19768354.2019.1595141

Endothelin-converting enzyme-1 expression in acute and chronic liver injury in fibrogenesis

Tae-Jun Cho a,b, Hyo-Jung Kim b, Jaejin Cho a,b,CONTACT
PMCID: PMC6566842  PMID: 31231580

ABSTRACT

Endothelin-1 (ET-1) induces contraction, proliferation, and collagen synthesis of activated hepatic stellate cells and is a potent mediator of portal hypertension. Endothelin-converting enzyme-1 (ECE-1) generates ET-1 from the inactive precursor big-endothelin-1. The cellular distribution and activity of ECE-1 in the liver is unknown. Hepatic fibrogenesis was induced in rats by CCl4 administration and secondary biliary cirrhosis after 6 weeks of complete bile duct occlusion (BDO). The tissue ET-1 and ET receptor protein levels were quantified, the ECE-1 isoform mRNAs were measured by RNase protection assay and ECE-1 activity was analyzed. ECE-1a and -b mRNA were upregulated in biliary cirrhosis and in CCl4-injured livers, whereas ECE-1c mRNA remained unchanged. ECE-1 activity was increased after BDO and peaked at 12 h after acute CCl4-intoxication. Tissue levels of ET-1, ETA- and ETB receptors were elevated 7-, 5-, and 4.6-fold in cirrhotic rats, respectively. ECE-1 activity increased following BDO and acute CCl4-intoxication. In conclusion, ECE-1a and -b RNAs are upregulated in fibrogenesis, indicating that these isoforms play a central role in ET-1 generation during fibrogenesis and portal hypertension.

KEYWORDS: Endothelin-converting enzyme-1, endothelin-1, hepatic fibrogenesis, endothelin receptor

Introduction

Endothelins (ETs) comprise a family of three homologous 21-amino acid oligopeptide vasoactive mediators (ET-1, ET-2, and ET-3) that trigger various biological effects through G protein-coupled specific receptors, namely the ETA receptor and ETB receptor (ETAR and ETBR, respectively). ET-1 usually induces a long-lasting vasoconstriction via ETAR and vasodilation via ETBR (Barman 2007; Martell et al. 2010; Ling et al. 2012).

The biological precursor of ET-1, prepro-ET-1, is converted to biologically active ET-1 through two steps. Initial cleavage of two basic amino acids by a furin-like enzyme results in big-ET-1, which is further processed by cleavage of a Trp-Val bond by endothelin converting enzyme-1 (ECE-1) producing biologically active ET-1. ECE-1 is a membrane-bound, phosphoramidon-sensitive metalloproteinase (Rodriguez-Pascual et al. 2014).

Several ECE-1 isoforms have been identified (Figure 1). ECE-1b and -c are characterized by isoform-specific exon 1, which are spliced to exon 2 that is common to both of these isoforms. ECE-1a is transcribed from an alternative promoter located about 11 kb downstream of exon 2. The 5′-terminus of exon 3 is the first ECE-1a specific exon, whereas the 3′-terminal part of this exon is common to all ECE-1 isoforms (Valdenaire et al. 1995; Orzechowski et al. 1997; Schweizer et al. 1997). Furthermore, an additional isoform that is generated from exon 1d located within the small (approx.. 200 bp) genomic region between exon 1b and exan 2, ECE-1d, was recently identified (Muller et al. 2003). ECE-1 is upregulated in congestive heart failure (Kohan et al. 2011), gastric injury (Slomiany and Slomiany 2005) and buccal mucosal ulcer healing after chronic alcohol ingestion in rats (Slomiany et al. 2000), and in lung cancer (Moody et al. 2017).

Figure 1.

Figure 1.

Open in a new tab

Genomic structure and mRNA isoforms generated from the rat ECE-1 gene. 

Note: The genomic structure of the 5′-terminal part of the rat ECE-1 gene with exon-intron boundaries and localizations of the alternative promoters is shown in the upper part. Exons 4–19, which are common to all isoforms, are not shown. ECE-1 isoforms 1a, 1b, and 1c transcribed by different promoters are shown in the lower part.

In the liver, the endothelin system is a modulator of portal hypertension and fibrogenesis. Mediated through the ETAR, ET-1 stimulates proliferation and contraction of hepatic stellate cells (HSC). This profibrogenic effect was significantly ameliorated in a model of rat biliary fibrosis following bile duct occlusion (BDO) by treatment with an orally active, highly specific ETAR antagonist, as evidenced by reduced hepatic collagen accumulation (Cho et al. 2000). As a key enzyme to the ET-1/ET receptor-system, ECE-1 and its isoforms may constitute additional targets for pharmacological intervention. A recent study suggested that ECE-1 transcripts were downregulated, whereas ECE-1 protein expression was increased in hepatic stellate cells isolated from fibrotic rat livers. Furthermore, the activity of ECE-1 did not change after liver injury induced by carbon tetrachloride and bile duct ligation in rats (Hocher et al. 2011). However, neither cellular sources nor expression levels of ECE-1 or its isoforms were studied in vivo. Therefore, we investigated the temporospatial expression patterns of ECE-1 at the RNA level by in situ hybridization and isoform-specific RNase protection assays and related these to ECE-1 activity in acute and chronic liver fibrogenesis.

Material and methods

Animals and experimental design

All animal experiments were conducted in accordance with German state laws approving and governing the use of experimental animals. Ten week old female Wistar rats (Schoenwalde, Germany., approx. 250 g) were maintained under 12-hour light–dark cycles and at 23 ± 2°C with a humidity of 60 ± 10%. During the experiment, the animals received pellet chow diet freely (Ssniff, Germany). The rats were used for induction of secondary biliary fibrosis by complete bile duct occlusion (BDO) and scission following retrograde injection of Ethibloc (sodium amidotrizate) as previously described (Cho et al. 2000; Karsdal et al. 2016; Santos-Laso et al. 2017). Animals were sacrificed after 6 weeks when tissue hepatic collagen is increased 8–12 fold served as controls. Acute fibrogenesis was induced in 7 week old male rats (weight approx. 125 g) by a single dose of carbon tetrachloride (CCl4) (Sigma, St. Louis, MO, USA) injected intraperitoneally at 1.25 ml/kg body weight and sacrificed in groups of 6, 12, 24, 48, and 72 h animals.

Determination of hepatic ET-1, and of ETA and ETB receptor levels

Analysis of tissue ET-1 concentration was conducted as previously described (Cho et al. 2000; Kocyigit et al. 2018). Briefly, Snap-frozen liver tissue (approx. 200 mg) was powdered in liquid nitrogen and homogenized at 4°C. Homogenates were then centrifuged at 4°C for 60 min at 100,000 × g, after which supernatants were analyzed for ET-1 content using the commercial enzyme immunoassay (Biomedica, Vienna, Austria). Cross-reactivities were as follows: ET-1 (1–21): 100%; ET-2 (1–21): 100%; ET-3 (1–21): < 5%; big-ET-1 (1–38): < 1%; big-ET-2 (22–38): < 1%. ET receptors were determined by radioligand assays (Cho et al. 2000) in the presence or absence of the subtype-specific endothelin receptor antagonists BQ123 (3 µmol/l, ETAR specific) (Sigma, St. Louis, USA) and/or BQ3020 (3 µmol/l, ETBR specific) (Sigma, St. Louis, USA). Next, 1 ml of cold binding buffer was added and centrifugated at 30,000 × g and 4°C for 15 min and receptor-bound [125I]-ET-1 was counted in a Packard Gamma Counter with 78% counting efficiency for [125I].

Cloning of cDNA probes and multiprobe RNase protection assay

The cDNA for rat endothelin converting enzyme-1 (ECE-1) covering coding positions 1–441 bp was prepared from rat liver tissue by RT–PCR amplification according to the published sequence (Shimada et al. 1994) (GenBank accession number: D 29683, sense primer: TGCGGTCGGAGCGTAGAGCT, antisense primer: ACCACAGGCGTAGCTGAAGAA), verified by sequence analysis and cloned into pZErO-1 (Invitrogen, San Diego, CA, USA). The probe was designed to detect the three different ECE-1 isoforms (ECE-1a, b, and c). The protected sequences were as follows: ECE-1a, 260 bp; ECE-1b, 340 bp; ECE-1c, 439 bp (Figure 1). Internal standardization was conducted using a 102 bp GAPDH probe (from position 335 to 437, M17701). Preparation of total RNA and RNase protection assays were performed as described previously (Cho et al. 2000). Briefly, after extraction of RNA using acid guanidinium thiocyanate-phenol–chloroform, the integrity of all samples was documented by visualization of 18S and 28S ribosomal bands after electrophoresis. Radiolabeled cRNA was produced by in vitro transcription with T7 polymerase (Ambion, Austin, TX, USA) using [α-32P] UTP (800 Ci/mmol, 10 mCi/mL; NEN, Boston, MA, USA), followed by incubation with 105 cpm of 32P-labeled cRNA, denaturation at 95°C and overnight hybridization at 42°C. Following hybridization, RNase A and T1 (Ambion, Austin, TX, USA) digestion of unbound labels and unprotected mRNA was conducted. The protected RNA-RNA hybrids were denatured and separated by electrophoresis through a 5% polyacrylamide/8M urea sequencing gel, after which the gel was exposed to an X-ray film for 48 h. Autoradiograms were analyzed with the public domain NIH Image program. Signals for ECE-1 isoform mRNAs were normalized to the signal for GAPDH mRNA and expressed as relative abundance (arbitrary units). The differences in relative abundance of mRNAs were analyzed by the Kruskal–Wallis test.

Endothelin-converting enzyme activity

Endothelin-converting enzyme activity was measured by the production rate of endothelin-1 from big-endothelin with minor modifications of a previously reported method (Mitani et al. 2000). Briefly, membrane-bound proteins were enriched by homogenization of 100 mg liver tissue in 1 ml 20 mM Tris-HCl, pH 7.4, containing 5 mM MgCl2, 20 µM pepstatin A, 20 µM leupeptin, and 50 µM p-amidinophenyl methanesulphonyl fluoride (homogenization buffer). The homogenates were then centrifuged at 1,000 g and 4°C for 10 min to remove cell debris, followed by high-speed centrifugation of 200 µl of the supernatant at 100,000 g and 4°C for 45 min. The resultant pellets were solubilized in homogenization buffer containing 0.5% (w/v) Triton X-100 and centrifuged again (100,000 g, 4°C for 60 min), after which the supernatant was transferred to fresh tubes. Next, 25 μL of the supernatant was diluted with 100 µL assay buffer (20 mM Tris-HCl, pH 6.8, containing 100 nM big endothelin-1, 0.1% (w/v) bovine serum albumin, 20 µM pepstatin A, 20 µM leupeptin) and incubated for 2 h at 37°C. The reaction was stopped with 125 µL 5 mM EDTA and the concentration of generated ET-1 determined with the endothelin ELISA kit as described above. This was normalized to protein concentration as measured by the Micro BCA assay kit (Pearce, Rockford, IL, USA).

Statistics

Statistical analysis was performed using analysis of variance, Duncan's multiple range test for differences between groups, and Pearson's correlation coefficient.

Results

Tissue endothelin-1 and endothelin receptor protein tissue levels

Hepatic levels of ET-1, ETAR and ETBR were increased 7.2-, 7.35- and 4.9-fold, respectively, in BDO rats compared to the normal control group (p < 0.001), indicating a strong activation of the endothelin system in chronic liver fibrogenesis (Figure 2).

Figure 2.

Figure 2.

Open in a new tab

Upregulation of tissue endothelin-1 and endothelin A and B receptor levels in rats with secondary biliary cirrhosis.

Note: BDO, bile duct occlusion; Sham, sham operation as a negative control. ETAR, endothelin A receptor; ETBR, endothelin B receptor. *, P <  0.05 vs. control.

Patterns of ECE-1 mRNA expression in normal liver and in hepatic fibrogenesis

In situ hybridization with [35S]-labeled RNA probes was used to define the cellular source of ECE-1 expression. In normal liver, ECE-1 transcript levels were homogeneously distributed over hepatocytes. Some perisinusoidal nonparenchymal cells also expressed ECE-1 RNA at levels similar to hepatocytes. Slightly increased signals were found over endothelial cells of the portal and terminal hepatic veins and arteries. Occasionally, bile duct epithelia showed low-level ECE-1 RNA expression.

Compared to normal liver cells, all hepatic cells displayed increased ECE-1 transcript levels in biliary cirrhosis. Hepatocytes as well as perisinusoidal cells were the major locations of ECE-1 mRNA expression, whereas ECE-1 specific autoradiographic signals remained lower in bile duct cells and portal fibroblasts.

At 24 h after injection of CCl4, ECE-1 transcript levels increased over perisinusoidal as well as central/portal venular and arterial endothelial cells. Some of these cells were desmin positive, indicating they were activated stellate cells or myofibroblasts. As in the BDO model of chronic fibrogenesis, ECE-1 RNA predominated in hepatocytes. Desmin-positive cells adjacent to pericentral areas of necrosis showed higher levels of ECE-1 mRNA than hepatocytes, whereas bile duct epithelia displayed lower ECE-1 RNA levels compared to hepatocytes.

Expression of ECE-1 isoform mRNAs in acute and chronic hepatic fibrogenesis

To differentiate the expression patterns of the three ECE-1 isoform mRNAs (ECE-1a, -1b and -1c), an ECE-1 cDNA probe that allowed detection of the three isoforms during the RNase protection assay was generated. After 6 weeks of BDO as well as after a single dose of CCl4, expression of the predominant ECE-1c isoform remained unchanged. However, ECE-1a and -1b isoform mRNAs were increased slightly by 1.3–1.4 fold in biliary fibrosis and 1.5–2.2 fold at 48 h after CCl4-induced acute liver injury (p < 0.05), respectively (Figure 3). After CCl4 intoxication, both ECE-1a and -1b isoforms increased in a time-dependent manner, with the maximum occurring after 48 h (Figure 4).

Figure 3.

Figure 3.

Open in a new tab

Upregulation of endothelin converting enzyme-1 a and b, but not c isoform mRNA in rats with secondary biliary cirrhosis.

Note: Multiprobe-RNase protection assay. (A) Autography and (B) relative abundance of endothelin converting enzyme-1 a and -1 b isoform mRNAs. P, cRNA probes, T, negative control containing transfer RNA; Control, normal liver; BDO, BDO alone as positive control; *, P <  0.05 vs. control.

Figure 4.

Figure 4.

Open in a new tab

Dynamics of endothelin converting enzyme-1 isoform mRNAs expression in rats with acute carbon tetrachloride intoxication.

Note: Multiprobe-RNase protection assay. (A) Autography and (B) relative abundance of endothelin converting enzyme-1 a and -1 b isoform mRNAs. P, cRNA probes, T, negative control containing transfer RNA; N, normal liver.

ECE-1 activity in biliary fibrosis and after acute CCl4 intoxication

We measured the activity of ECE-1 to clarify whether the increases in ECE-1a and -1b isoform mRNAs were coupled with enhanced ECE-1 enzymatic activity, as reflected by increased in vivo generation of ET-1. In biliary fibrosis, ECE-1 activity increased 7-fold compared to the normal controls (p < 0.05) (Figure 5). After acute CCl4 intoxication, ECE-1 activity (Figure 5(B)).

Figure 5.

Figure 5.

Open in a new tab

Endothelin-converting enzyme-1 activity.

Note: Conversion of big ET-1 to ET-1 by ECE-1 in solubilized membrane fractions of rat liver tissues. (A) ECE-1 activity in acute liver injury induced by carbon tetrachloride and (B) in advanced liver fibrosis due to bile duct occlusion for 6 weeks by rat secondary biliary fibrogenesis.

Discussion

The endothelin system plays an important role in vascular homeostasis and various pathophysiological processes, including liver diseases. Thus, it is activated in cardiovascular diseases (Kalk et al. 2011) and atherosclerosis (Huang 2009), pulmonary disease (Moody et al. 2017) and hepatic fibrosis (Cho et al. 2000). ECE-1, of which there are at least four isoforms, is the key enzyme involved in ET-activation and may play an important role in hepatic fibrogenesis and other diseases. Because little is known about ECE-1 expression in the liver, we investigated the expression patterns of ECE-1 and its isoforms during acute and chronic hepatic fibrogenesis.

Because tissue levels of ET-1, ETAR and ETBR are upregulated during liver fibrogenesis while the ET-1 processor big-ET-1 remains unchanged (Figure 2), ECE-1 should serve as the gatekeeper for enhanced ET production.

We found that ECE-activity increased by 1.3–1.4 fold in BDO and after acute (CCl4-induced) fibrogenesis. This was reflected by moderate, up to 1.3 and 1.4 fold increased expression of hepatic ECE-1a and -1b mRNA, respectively, whereas ECE-1c mRNA remained unchanged. Because parenchymal ECE-1 mRNA was constitutive constitutive and that by endothelial as well as some desmin-positive (myofibroblastic) cells upregulated, it may be speculated that ECE-1a and -1b isoforms are mainly produced by nonparenchymal cells and upregulated during fibrogenesis.

Our results are in accordance with those of previously conducted studies. For example, tissue ECE activity is correlated with coronary artery disease (Nguyen et al. 2010), while ECE-1 activity was show to be upregulated during buccal mucosal ulcer (Slomiany et al. 2000) and gastric ulcer (Slomiany and Slomiany 2005) in rats and accompanied by the induction of TNF-α and apoptosis. Furthermore, inhibition of ECE-1 attenuated atherosclerosis (Grantham et al. 2000) and hypertension (Takeda et al. 2000). Summarizing those results indicates that the ET-system, especially ECE, might play a crucial role in the pathophysiology of tissue regeneration. Similarly, our data confirmed that ECE is of great importance to liver fibrogenesis. However, the results of the present study contradicted those of Shao et al., who showed that the ECE-1 mRNA level in hepatic stellate cells was reduced and ECE-1 protein content was increased in liver fibrosis (Nagata et al. 2005; Hocher et al. 2011). These differences likely occurred because of differences in the experimental model. Specifically, Shao et al. used freshly isolated hepatic stellate cells, whereas we used whole liver tissues. Because ECE-1 mRNA expression was widely distributed in not only HSC, but also hepatocytes, perisinusoidal cells, and venular/arterial endothelial cells, the action of ECE-1 is not limited to HSC. Furthermore, the different expression patterns depend on ECE-1 isoforms.

Overall, the results of this study indicate that modulation of ECE-1 isoform expression might play a key role in ET-system activation in liver fibrogenesis.

Funding Statement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 860-20180051).

Acknowledgments

This research was supported by the Institute for Information & Communication Technology Promotion (IITP) through the National Research Foundation (NRF) funded by the South Korean government (860-20180051).

Disclosure statement

No potential conflict of interest was reported by the authors.

References

  1. Barman SA.2007. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am J Physiol Lung Cell Mol Physiol. 293:L472–L479. doi: 10.1152/ajplung.00101.2006 [DOI] [PubMed] [Google Scholar]
  2. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, Riecken EO, Schuppan D.. 2000. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 118:1169–1178. doi: 10.1016/S0016-5085(00)70370-2 [DOI] [PubMed] [Google Scholar]
  3. Grantham JA, Schirger JA, Wennberg PW, Sandberg S, Heublein DM, Subkowski T, Burnett JCJ.. 2000. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. Circulation. 101:1976–1981. doi: 10.1161/01.CIR.101.16.1976 [DOI] [PubMed] [Google Scholar]
  4. Hocher B, Heiden S, von Websky K, Rahnenführe J, Kalk P, Pfab T.. 2011. Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure. Eur J Med Res. 16:275–279. doi: 10.1186/2047-783X-16-6-275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Huang PL.2009. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 20:295–302. doi: 10.1016/j.tem.2009.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, et al. . 2011. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension. 57:755–763. doi: 10.1161/HYPERTENSIONAHA.110.163972 [DOI] [PubMed] [Google Scholar]
  7. Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T, Schuppan D.. 2016. Collagen and tissue turnover as a function of age: implications for fibrosis. J Hepatol. 64:103–109. doi: 10.1016/j.jhep.2015.08.014 [DOI] [PubMed] [Google Scholar]
  8. Kocyigit I, Eroglu E, Kaynar AS, Kocer D, Kargi S, Zararsiz G, Bayramov R, Imamoglu H, Sipahioglu MH, Tokgoz B, et al. . 2018. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients. J Nephrol. 32:83–91. doi: 10.1007/s40620-018-0514-2 [DOI] [PubMed] [Google Scholar]
  9. Kohan DE, Rossi NF, Inscho EW, Pollock DM.. 2011. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 91:1–77. doi: 10.1152/physrev.00060.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP.. 2012. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. Life Sci. 91:716–722. doi: 10.1016/j.lfs.2012.02.003 [DOI] [PubMed] [Google Scholar]
  11. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J.. 2010. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2:208–220. doi: 10.4254/wjh.v2.i6.208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mitani H, Takimoto M, Bandoh T, Kimura M.. 2000. Increases of vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol. 387:313–319. doi: 10.1016/S0014-2999(99)00808-0 [DOI] [PubMed] [Google Scholar]
  13. Moody TW, Ramos-Alvarez I, Moreno P, Mantey SA, Ridnour L, Wink D, Jensen RT.. 2017. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides. 90:90–99. doi: 10.1016/j.peptides.2017.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Muller L, Barret A, Etienne E, Meidan R, Valdenaire O, Corvol P, Tougard C.. 2003. Heterodimerization of endothelin-converting enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease. J Biol Chem. 278:545–555. doi: 10.1074/jbc.M208949200 [DOI] [PubMed] [Google Scholar]
  15. Nagata T, Kudo H, Nishino T, Doi Y, Itoh H, Fujimoto S.. 2005. Increased immunoreactivities against endothelin-converting enzyme-1 and monocyte chemotactic protein-1 in hepatic stellate cells of rat fibrous liver induced by thioacetamide. Med Mol Morphol. 38:161–172. doi: 10.1007/s00795-005-0292-5 [DOI] [PubMed] [Google Scholar]
  16. Nguyen A, Thorin-Trescases N, Thorin E.. 2010. Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol. 298:R1188–R1194. doi: 10.1152/ajpregu.00653.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Orzechowski HD, Richter CM, Funke-Kaiser H, Kröger B, Schmidt M, Menzel S, Bohnemeier H, Paul M.. 1997. Evidence of alternative promoters directing isoform-specific expression of human endothelin-converting enzyme-1 mRNA in cultured endothelial cells. J Mol Med (Berl). 75:512–521. doi: 10.1007/s001090050136 [DOI] [PubMed] [Google Scholar]
  18. Rodriguez-Pascual F, Busnadiego O, Gonzalez-Santamaria J.. 2014. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? Life Sci. 118:156–164. doi: 10.1016/j.lfs.2013.12.024 [DOI] [PubMed] [Google Scholar]
  19. Santos-Laso A, Munoz-Garrido P, Felipe-Agirre M, Bujanda L, Banales JM, Perugorria MJ.. 2017. New advances in the molecular mechanisms driving biliary fibrosis and emerging molecular targets. Curr Drug Targets. 18:908–920. doi: 10.2174/1389450116666150427155035 [DOI] [PubMed] [Google Scholar]
  20. Schweizer A, Valdenaire O, Nelböck P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Löffler BM.. 1997. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J. 328:871–877. doi: 10.1042/bj3280871 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shimada K, Takahashi M, Tanzawa K.. 1994. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem. 269:18275–18278. [PubMed] [Google Scholar]
  22. Slomiany BL, Piotrowski J, Slomiany A.. 2000. Suppression of endothelin-converting enzyme-1 during buccal mucosal ulcer healing: effect of chronic alcohol ingestion. Biochem Biophys Res Commun. 271:318–322. doi: 10.1006/bbrc.2000.2634 [DOI] [PubMed] [Google Scholar]
  23. Slomiany BL, Slomiany A.. 2005. Endothelin-1-dependent up-regulation of leptin production in gastric mucosal injury by indomethacin. Inflammopharmacology. 13:455–466. doi: 10.1163/156856005774649331 [DOI] [PubMed] [Google Scholar]
  24. Takeda Y, Inaba S, Furukawa K, Fujimura A, Miyamori I, Mabuchi H.. 2000. Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension. J Hypertens. 18:927–933. doi: 10.1097/00004872-200018070-00015 [DOI] [PubMed] [Google Scholar]
  25. Valdenaire O, Rohrbacher E, Mattei MG.. 1995. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem. 270:29794–29798. doi: 10.1074/jbc.270.50.29794 [DOI] [PubMed] [Google Scholar]

Articles from Animal Cells and Systems are provided here courtesy of Taylor & Francis

RESOURCES